Breaking News

Advinus Earns Takeda Milestone

By Kristin Brooks | January 7, 2014

R&D collaboration completes first successful year

Advinus Therapeutics Ltd., the TATA promoted Pharmaceutical R&D Co., has received a $3 million milestone for the first successful year in its R&D collaboration with Takeda Pharmaceutical Co.
 
In October 2012, the companies entered a multi-year, multi-project drug discovery collaboration. Advinus is responsible for carrying out all research required to identify candidate molecules for clinical development in several therapeutic areas, and Takeda is responsible for development and commercialization.
 
"Achievement of the rather challenging first year milestone can be attributed to the truly collaborative nature of our relationship with Takeda as well as Advinus' ability to solve complex problems with efficiency and speed,” said Kasim Mookhtiar, chief scientific officer of Advinus.

Related Contract Manufacturing:

blog comments powered by Disqus
  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent

  • Successful Method Transfer of Solid Oral Dosage

    Successful Method Transfer of Solid Oral Dosage

    John Frankonis, Ropack Pharma Solutions||June 2, 2016
    The three steps outlined will help guide the process of completing a successful analytical method transfer

  • Who’s the Right Service Provider for You?

    Who’s the Right Service Provider for You?

    Raymond Peck, VxP Pharma Services||June 2, 2016
    Factors to consider when choosing between using one integrated CDMO or a series of smaller functional service providers